Clinuvel Pharmaceuticals (FRA:UR9) Institutional Ownership : 11.83% (As of Apr. 29, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Clinuvel Pharmaceuticals's institutional ownership is 11.83%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Clinuvel Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Clinuvel Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 0.00%.

Clinuvel Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Institutional Ownership Chart

Clinuvel Pharmaceuticals Historical Data

The historical data trend for Clinuvel Pharmaceuticals can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	11.61	11.56	11.55	11.34	11.32	11.47	11.71	11.86	11.82	11.83

Clinuvel Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Clinuvel Pharmaceuticals (FRA:UR9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (FRA:UR9) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

CLVLY:USA CLVLF:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (FRA:UR9) Headlines

No Headlines